Profile data is unavailable for this security.
About the company
Fagron NV, formerly Arseus NV, is a Belgium-based company that is active in the healthcare sector. The Company specializes in the development, marketing and distribution of healthcare products and services intended for healthcare professionals and institutions. It operates through the following segments: Essentials, enable pharmacists to compound safe products and optimize their compounding process with equipment and packaging. The portfolio includes pharmaceutical raw materials, compounding equipment, packaging, and supplies; Brands, focuses on developing semi-finished products and pharmaceutical-grade vehicles and reduce the workload for pharmacists; Compounding Services, utilizes raw materials from the Essentials segment and vehicles from the Brands segment for compounding activities, offering both sterile and non-sterile compounded products tailored to patients' specific needs.
- Revenue in EUR (TTM)--
- Net income in EUR--
- Incorporated2007
- Employees3.99k
- LocationFagron NVVenecoweg 20ANAZARETH 9810BelgiumBEL
- Phone+32 80012880
- Fax+32 92162491
- Websitehttps://fagron.com/
More ▼
Mergers & acquisitions
| Acquired company | FAGR:BRU since announced | Transaction value |
|---|---|---|
| Ricaro Importacao Industria e Comercio de Embalagens e Insumos Ltda | 9.40% | -- |
| Amber Compounding Pharmacy Pte Ltd | 9.40% | -- |
| MagiLab Kft | 9.66% | -- |
| Zaklad Farmaceutyczny Amara Sp z o o | 9.66% | 29.93m |
| University RX Specialists Inc | 15.82% | 41.50m |
Data delayed at least 15 minutes, as of Feb 17 2026 16:35 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sihuan Pharmaceutical Holdings Group Ltd | 256.21m | -9.85m | 1.62bn | 2.77k | -- | 3.04 | -- | 6.32 | -0.0098 | -0.0098 | 0.2572 | 0.5396 | 0.1894 | 1.49 | 3.86 | 889,784.80 | -3.05 | -3.60 | -5.01 | -5.05 | 66.29 | 73.13 | -16.08 | -19.74 | 1.61 | -1.36 | 0.1606 | -- | 2.18 | -7.96 | -301.10 | -- | -20.58 | 3.60 |
| Organon & Co | 5.32bn | 422.75m | 1.62bn | 10.00k | 3.84 | 2.12 | 2.28 | 0.3049 | 1.92 | 1.92 | 24.20 | 3.48 | 0.4791 | 1.97 | 3.98 | 630,100.00 | 3.81 | 11.52 | 4.81 | 14.94 | 55.04 | 62.30 | 7.95 | 20.24 | 1.20 | 2.50 | 0.9069 | 16.02 | 2.24 | -3.81 | -15.54 | -23.54 | 30.71 | -- |
| CF PharmTech Inc | 73.77m | 3.39m | 1.62bn | 574.00 | 478.90 | 13.86 | 146.46 | 21.99 | 0.0762 | 0.0762 | 1.66 | 2.63 | -- | -- | -- | -- | -- | -- | -- | -- | 80.18 | -- | 4.60 | -- | 1.89 | -- | 0.076 | -- | 9.23 | -- | -33.53 | -- | -- | -- |
| Ocular Therapeutix Inc | 43.84m | -224.40m | 1.63bn | 325.00 | -- | 2.93 | -- | 37.21 | -1.44 | -1.44 | 0.2775 | 3.03 | 0.0821 | 1.99 | 1.65 | 159,849.20 | -42.01 | -38.63 | -45.31 | -43.31 | 87.35 | 90.18 | -511.90 | -229.54 | 15.32 | -- | 0.0983 | -- | -18.47 | 24.45 | -37.43 | -- | 70.20 | -- |
| FAES Farma SA | 568.11m | 105.08m | 1.64bn | 756.00 | 15.44 | -- | 12.73 | 2.89 | 0.336 | 0.336 | 1.82 | -- | -- | -- | -- | 320,062.00 | -- | 13.17 | -- | 15.13 | 65.15 | 64.65 | 18.49 | 20.72 | -- | 155.55 | -- | -- | 9.42 | 6.67 | 21.17 | 11.73 | 13.09 | -- |
| Tibet Rhodiola Pharmaceutical Holding Co | 332.28m | 119.84m | 1.64bn | 596.00 | 13.72 | 3.79 | -- | 4.95 | 3.04 | 3.04 | 8.44 | 11.02 | 0.5188 | 1.38 | 6.52 | 4,564,666.00 | 18.84 | 14.99 | 25.61 | 19.30 | 92.08 | 92.11 | 36.31 | 23.95 | 2.89 | -- | 0.1971 | 52.89 | -10.45 | 17.45 | 31.26 | 27.47 | -5.16 | 27.43 |
| Fagron NV | -100.00bn | -100.00bn | 1.65bn | 3.99k | -- | 2.98 | -- | -- | -- | -- | -- | 7.51 | -- | -- | -- | -- | -- | 7.72 | -- | 9.52 | -- | 44.06 | -- | 9.75 | 1.39 | -- | 0.457 | 20.58 | 9.20 | 11.36 | 12.99 | 8.84 | 10.69 | 17.32 |
| Ultragenyx Pharmaceutical Inc | 567.65m | -485.57m | 1.67bn | 1.29k | -- | -- | -- | 2.94 | -5.84 | -5.84 | 6.82 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 83.85 | 88.44 | -85.54 | -122.25 | -- | -12.60 | -- | -- | 20.13 | 19.95 | -1.02 | -- | -- | -- |
| Bora Pharmaceuticals Co Ltd | 535.31m | 123.56m | 1.68bn | 91.00 | 14.37 | 5.36 | 10.77 | 3.14 | 34.10 | 24.33 | 143.28 | 91.50 | 0.4537 | 2.76 | 2.11 | -- | 10.60 | 11.35 | 16.48 | 18.81 | 39.99 | 39.47 | 23.36 | 19.44 | 1.07 | -- | 0.5549 | 37.72 | 35.53 | 65.95 | 29.99 | 66.80 | -0.3363 | 74.57 |
| Perrigo Company PLC | 3.61bn | -24.64m | 1.69bn | 8.38k | -- | 0.45 | 6.61 | 0.4673 | -0.2128 | -0.3764 | 31.00 | 32.31 | 0.4023 | 2.34 | 5.75 | 511,015.60 | -0.2743 | -0.7059 | -0.3124 | -0.8082 | 35.46 | 34.96 | -0.682 | -1.76 | 1.44 | 2.41 | 0.4505 | -- | -6.06 | 2.48 | -3,552.27 | -- | -16.23 | 18.65 |
| EIS czcbs lc Sn v Fnnsl Ytrmlr Sny v Tcr | 171.67m | 47.02m | 1.70bn | 1.10k | 36.24 | 1.54 | 26.99 | 9.93 | 3.55 | 3.55 | 12.98 | 83.78 | 0.1393 | 3.47 | 5.91 | 8,173,382.00 | 3.81 | 6.40 | 4.07 | 6.86 | 26.87 | 33.31 | 27.39 | 40.47 | 1.87 | -- | 0.0602 | 27.65 | -6.28 | 58.48 | -74.12 | 44.46 | 151.56 | 88.80 |
| Tsumura & Co | 1.04bn | 159.47m | 1.71bn | 4.27k | 10.45 | 0.9878 | 7.28 | 1.64 | 387.15 | 387.15 | 2,524.84 | 4,095.99 | 0.374 | 0.7106 | 2.41 | 44,357,680.00 | 6.01 | 5.53 | 8.06 | 6.85 | 47.60 | 49.39 | 16.06 | 14.50 | 1.45 | -- | 0.2856 | 31.65 | 20.05 | 8.00 | 94.10 | 18.69 | 23.07 | 16.27 |
Data as of Feb 17 2026. Currency figures normalised to Fagron NV's reporting currency: Euro EUR
48.57%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Goldman Sachs Asset Management BVas of 23 Apr 2025 | 13.21m | 17.93% |
| Active Ownership Corp SARLas of 23 Apr 2025 | 8.10m | 11.00% |
| Mawer Investment Management Ltd.as of 23 Apr 2025 | 3.68m | 4.99% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 2.38m | 3.23% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 1.99m | 2.70% |
| abrdn Investment Management Ltd.as of 31 Oct 2025 | 1.81m | 2.46% |
| BNP Paribas Asset Management Belgium SAas of 30 Jan 2026 | 1.22m | 1.65% |
| Amundi Asset Management SASU (Investment Management)as of 02 Feb 2026 | 1.15m | 1.57% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 1.13m | 1.53% |
| Tweedy, Browne Co. LLCas of 28 Nov 2025 | 1.12m | 1.52% |
More ▼
Data from 09 Sep 2025 - 12 Feb 2026Source: FactSet Research Systems Inc.
